Category Menu Product News

Genesis’s PVC-free material chosen for stabilizing device by medical company

Genesis Plastics Welding, a manufacturer of Radio Frequency (RF) welded products based in the

US, announced on July 19 it is in collaboration with REDpoint International, a medical device company, to produce the StedLine IV Sleeve, a stabilizing device that eliminates the need for glue or tape to secure an intravenous line to skin.

REDpoint’s primary manufacturing goal was to eliminate PVC while still keeping the product cost-efficient, safe and patient-friendly. Genesis provides REDpoint with lower-cost PE and PET materials suited for single-use medical products such as the IV sleeve yet robust enough to provide the desired product strength.

“With our latest product, the StedLine IV Sleeve, it was important that we find an RF plastics welding manufacturing partner within the United States who understood the importance and potential of our product within the medical device industry,” said Chuck Nokes, REDpoint Founder and President.

Throughout the initial production process, REDpoint went through multiple focus groups to test both the quality and comfort of the IV sleeve for patients. After each research round, Genesis’ engineering team worked with REDpoint executives to make needed changes to materials and processes while keeping manufacturing efficient and low-cost.

“With the help of Genesis’ proprietary RF welding technology, ecoGenesis, the finished product also features durable and attractive welds,” said Tom Ryder, Genesis Plastics Welding President and CEO.

As said, the REDpoint StedLine IV Sleeve has proven beneficial for elderly and pediatric patients, as it absorbs yanks and tugs that commonly cause IV catheters to fail.

A PVC-free medical device is important because medical devices made of certain PVCs can leach DEHP, which has been found to cause organ damage in animals, according to the American Medical Association. The US Food and Drug Administration (USFDA) has advised health care providers to reduce DEHP exposure for certain vulnerable populations, including infants and other patients receiving multiple medical treatments.


Source :

You may also like